Alzheimer antibody enters into phase IIb February 5, 2013 - News BioArctic’s monoclonal antibody for Alzheimer’s disease, BAN2401, has entered the next clinical study after successfully passed phase IIa. Safety and tolerability data indicate that BAN2401 is ...
